Asia-Pacific’s medical devices industry saw a drop of 17.14% in deal activity during May 2021, when compared with the last 12-month average, led by China Investment, EDBI, Novo Holdings and Vivo Capital’s $200m acquisition of Esco Micro, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 29 medical devices industry deals worth $802.4m were announced for the region in May 2021, against the 12-month average of 35 deals.
Of all the deal types, venture financing saw most activity in May 2021 with 25 transactions, representing an 86.2% share for the region.
In second place was M&A with four deals capturing a 13.8% share of the overall deal activity for the month.
In terms of value of deals, venture financing was the leading category in Asia-Pacific’s medical devices industry with $733.69m, followed by M&A deals totalled $68.71m.
Asia-Pacific medical devices industry deals in May 2021: Top deals
The top five medical devices deals accounted for 62.1% of the overall value during May 2021.
The combined value of the top five medical devices deals stood at $498.15m, against the overall value of $802.4m recorded for the month.
The top five medical devices industry deals of May 2021 tracked by GlobalData were:
1) China Investment, EDBI, Novo Holdings and Vivo Capital’s $200m venture financing of Esco Micro
2) The $93.34m venture financing deal with Kailian Medical Technology by Beijing Fuhai Schwab Investment Consulting, Eight Roads Ventures, Qiandao Investment Holding Group and Shenzhen Oriental Fortune Capital
3) Beijing Junlian Capital Management, CPE Yuanfeng, Eli Lilly Asia Fund (LAV), Hillhouse Ventures, Qiming Venture Capital, Sanzheng Health Investment, Taifu Capital, Temasek Holdings (HK) and Yunfeng Fund L.P’s $77.78m venture financing of Jiangsu Hailai Xinchuang Medical Technology
4) The $64.89m venture financing of Shanghai Diluo Medical Equipment by Bohang Capital, CPE Funds Management, Insight Capital and Legend Capital
5) Fosun Pharma, Gao Ling (Tianjin) Venture Capital, LYFE Capital and SoftBank China Capital’s venture financing of Hangzhou Jianjia Robot for $62.15m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.